Neuroinflammatory markers and cytokines

Neuroinflammatory markers and cytokines represent a diverse group of signaling proteins and molecular indicators that mediate the immune response within the central nervous system (CNS). These molecules, including pro-inflammatory cytokines like TNF-alpha, IL-1 beta, and IL-6, as well as anti-inflammatory mediators like IL-10, are primarily produced by activated microglia and astrocytes in response to injury or disease (NIH, 2022; Wikipedia, 2024). In neurodegenerative conditions such as Alzheimer's and Parkinson's disease, chronic dysregulation of these markers leads to persistent neuroinflammation, which contributes to synaptic dysfunction and neuronal death (MDPI, 2024; Frontiers in Pharmacology, 2019). These markers also serve as critical tools for diagnosis and monitoring disease progression, with levels often measured in the cerebrospinal fluid or via specialized neuroimaging techniques like TSPO PET (NIH, 2024). Therapeutic strategies often focus on neutralizing specific pro-inflammatory cytokines or inhibiting the pathways that lead to their production using drugs like Anakinra or monoclonal antibodies (NIH, 2025). However, drug development faces significant challenges, including the need for effective blood-brain barrier penetration and the risk of suppressing the beneficial, neuroprotective aspects of the innate immune response (NIH, 2025; Frontiers in Immunology, 2013). Additionally, the dual role of many cytokines in both tissue repair and damage necessitates highly specific and timed interventions to avoid adverse effects.

Other names

Neuroinflammatory mediatorsPro-inflammatory cytokinesBrain inflammatory markersNeuroinflammation biomarkers

Neutralization of pro-inflammatory cytokines, antagonism of cytokine receptors, inhibition of inflammatory enzymes (e.g., COX-2), and modulation of glial activation states (NIH, 2021; Frontiers in Pharmacology, 2019).